|95.93||-1.62||-1.66%||Vol 2.30M||1Y Perf 9.01%|
|May 16th, 2022 16:00 DELAYED|
|- -||-0.50 -0.52%|
|Target Price||131.58||Analyst Rating||Strong Buy 1.32|
|Potential %||37.16||Finscreener Ranking||★★★+ 51.75|
|Insiders Trans % 3/6/12 mo.||-100/-96/-98||Value Ranking||★★★ 52.42|
|Insiders Value % 3/6/12 mo.||-100/-99/-100||Growth Ranking||★★★★★ 71.09|
|Insiders Shares Cnt. % 3/6/12 mo.||-100/-99/-100||Income Ranking||— -|
|Price Range Ratio 52W %||19.31||Earnings Rating||Sell|
|Market Cap||59.64B||Earnings Date||26th Apr 2022|
Today's Price Range
5 Year PE Ratio Range
|Moving Averages:||Strong Sell|
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||-|
|Estimated EPS Next Report||0.58|
|EPS Growth Next 5 Years %||12.90|
|Avg. Weekly Volume||3.26M|
|Avg. Monthly Volume||3.22M|
|Avg. Quarterly Volume||2.73M|
Edwards Lifesciences Corporation (NYSE: EW) stock closed at 95.93 per share at the end of the most recent trading day (a -1.66% change compared to the prior day closing price) with a volume of 2.30M shares and market capitalization of 59.64B. Is a component of S&P 500, Russell 1000 indices and it is traded on NYSE exchange. The company belongs in the Medical Devices & Instruments industry, Healthcare sector and employs 14900 people. Edwards Lifesciences Corporation CEO is Michael A. Mussallem.
The one-year performance of Edwards Lifesciences Corporation stock is 9.01%, while year-to-date (YTD) performance is -25.95%. EW stock has a five-year performance of 157.32%. Its 52-week range is between 87.36 and 131.73, which gives EW stock a 52-week price range ratio of 19.31%
Edwards Lifesciences Corporation currently has a PE ratio of 40.00, a price-to-book (PB) ratio of 10.38, a price-to-sale (PS) ratio of 11.13, a price to cashflow ratio of 35.70, a PEG ratio of 2.32, a ROA of 20.38%, a ROC of 25.64% and a ROE of 30.29%. The company’s profit margin is 28.70%, its EBITDA margin is 35.70%, and its revenue ttm is $5.36 Billion , which makes it $8.62 revenue per share.
Of the last four earnings reports from Edwards Lifesciences Corporation, there were 3 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $0.58 for the next earnings report. Edwards Lifesciences Corporation’s next earnings report date is -.
The consensus rating of Wall Street analysts for Edwards Lifesciences Corporation is Strong Buy (1.32), with a target price of $131.58, which is +37.16% compared to the current price. The earnings rating for Edwards Lifesciences Corporation stock is Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Edwards Lifesciences Corporation has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Edwards Lifesciences Corporation has a Sell technical analysis rating based on Technical Indicators (ADX : 8.35, ATR14 : 4.20, CCI20 : -82.09, Chaikin Money Flow : -0.24, MACD : -5.84, Money Flow Index : 17.91, ROC : -12.61, RSI : 34.36, STOCH (14,3) : 18.25, STOCH RSI : 0.81, UO : 37.29, Williams %R : -81.75), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Edwards Lifesciences Corporation in the last 12-months were: Bernard J. Zovighian (Option Excercise at a value of $0), Daveen Chopra (Option Excercise at a value of $1 086 640), Daveen Chopra (Sold 24 000 shares of value $2 398 989 ), Donald E. Bobo (Option Excercise at a value of $1 679 386), Donald E. Bobo (Sold 73 025 shares of value $8 026 965 ), Huimin Wang (Option Excercise at a value of $1 493 452), Huimin Wang (Sold 61 825 shares of value $6 971 094 ), Jean-Luc M. Lemercier (Option Excercise at a value of $507 443), Jean-Luc M. Lemercier (Sold 23 320 shares of value $2 584 387 ), Katie Szyman (Option Excercise at a value of $2 423 510), Katie Szyman (Sold 115 957 shares of value $12 918 606 ), Kieran T. Gallahue (Option Excercise at a value of $718 880), Kieran T. Gallahue (Sold 32 256 shares of value $3 573 510 ), Larry L. Wood (Option Excercise at a value of $2 337 567), Larry L. Wood (Sold 65 262 shares of value $7 126 507 ), Martha H. Marsh (Option Excercise at a value of $746 436), Martha H. Marsh (Sold 28 722 shares of value $3 104 563 ), Michael A. Mussallem (Option Excercise at a value of $10 520 960), Michael A. Mussallem (Sold 358 500 shares of value $39 525 860 ), Nicholas J. Valeriani (Buy at a value of $168 345), Scott B. Ullem (Option Excercise at a value of $0)
Wed, 27 Apr 2022 13:56 GMT Analysts Are Bullish on These Healthcare Stocks: Edwards Lifesciences (EW), Beauty Health (SKIN)- TipRanks. All rights reserved.
Wed, 27 Apr 2022 12:40 GMT Edwards Lifesciences (EW) Receives a Buy from Leerink Partners- TipRanks. All rights reserved.
Thu, 31 Mar 2022 16:08 GMT Edwards Lifesciences: Solid Business, Room to Improve- TipRanks. All rights reserved.
Fri, 25 Feb 2022 09:42 GMT Edwards Lifesciences Updates 1 Key Risk Factor- TipRanks. All rights reserved.
Fri, 28 Jan 2022 09:08 GMT Wall Street Analysts Are Neutral on Top Healthcare Picks- TipRanks. All rights reserved.
Thu, 27 Jan 2022 16:38 GMT Edwards Lifesciences (EW) Received its Third Buy in a Row- TipRanks. All rights reserved.
Thu, 27 Jan 2022 12:30 GMT Analysts Offer Insights on Healthcare Companies: Edwards Lifesciences (EW) and Anthem (ANTM)- TipRanks. All rights reserved.
Fri, 07 Jan 2022 16:34 GMT Morgan Stanley Believes Edwards Lifesciences (EW) Still Has Room to Grow- TipRanks. All rights reserved.
Copyright © 2016-2022 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex and Tradegate data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
eToro USA LLC does not offer CFDs and makes no representation and assumes no liability as to the accuracy or completeness of the content of this publication, which has been prepared by our partner utilizing publicly available non-entity specific information about eToro. Your capital is at risk.
This could take some time, please wait.